Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Open accessAbstract
Background & aims Ursodeoxycholic acid (UDCA) has been shown to be a safe and effective treatment for patients with primary biliary cirrhosis; however, its effect on patient survival is less certain. To study this issue, the survival of patients receiving long-term UDCA treatment was compared with that of a control group, adjusting for their risk scores based on the Mayo model.Methods One hundred eighty patients were randomized to receive either 13-15 mg.kg-1.day-1 UDCA (n = 89) of placebo (n = 91). After the study closure, the patients originally receiving placebo were switched to active drug, and prospective follow-up was continued for 3 years. Patients were censored at the time of transplantation, voluntary withdrawal, of crossover of the placebo group (efficacy analysis). The survival of the two groups was adjusted for risk scores at the time of entry to the study. A secondary analysis was an intent-to-treat analysis, whereby patients were followed up regardless of their voluntary withdrawal or crossover.Results At the time of analysis, the patients receiving placebo had a significantly increased risk of death and/or requiring transplantation (relative risk, 2.6; P = 0.04) compared with the UDCA-treated patients Conclusions UDCA should be considered as a safe, effective, and life-extending treatment for patients with primary biliary cirrhosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A number of studies have shown benefit of UDCA in PBC, with individual studies demonstrating consistent evidence of improved liver biochemistries.
“A number of studies have shown the benefit of UDCA in this context.(58)(59)(60)(61)(62)(63) Individual studies have demonstrated consistent evidence of improved liver biochemistries.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Still being checked.
Research works printed but not linked: 2
- Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, It is equivalent to removing the placebo curve from Fig- Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange ure 1 to Figure 4. In our case, the treatment effect is SM, LeSage G, Rossi SS, Hofmann AF. Ursodeoxycholic acid in overstated by 60% (5.9 vs. 3.6). For survival, the placebo the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:1284-1290. References Gastroenterology, Mayo Foundation, Rochester, Minnesota 55905. Fax: (507) 284-0538.
- Poupon RE, Balkau B, Eschwege E, Poupon R, UDCA-PBC Study Presented at the 1995 annual meeting of the American Gastroen- Group. A multicenter, controlled trial of Ursodiol for the treatment terological Association in San Diego, California. of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
Cited by
Sorted by citations
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241 · see citing works
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099 · see citing works
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · see citing works
Self-citationCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735 · see citing works
Self-citationHigh-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720 · see citing works
Self-citationBiochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · see citing works
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · see citing works
Self-citationUrsodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 420 · see citing works
Self-citationLucey, M. R., Brown, K., Everson, G. T., Fung, J. J., Gish, R. G., Keeffe, E. B., Kneteman, N. M., Lake, J. R., Martín, P., McDiarmid, S. V., et al. (1997) · Liver Transplantation and Surgery · doi:10.1002/lt.500030613 · Cited by 396 · see citing works
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R., & Poupon, R. Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 391 · see citing works
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372 · see citing works
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334 · see citing works
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315 · see citing works
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287 · see citing works
Ursodeoxycholic acid for primary biliary cirrhosis
Rudić, J. S., Poropat, G., Krstic, M. N., Bjelaković, G., & Gluud, C. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub3 · Cited by 274 · see citing works
Parés, A. R., Caballería, L., Rodés, J., Bruguera, M., Rodrigo, L., García-Plaza, A., Berenguer, J., Rodrı́guez-Martı́nez, D., Mercader, J., & Velicia, R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80216-0 · Cited by 268 · see citing works
Hirschfield, G. M., & Heathcote, E. J. (2010) · Wiley eBooks · doi:10.1002/9781444314403.ch32 · Cited by 260 · see citing works
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253 · see citing works
Fatigue in primary biliary cirrhosis
Cauch-Dudek, K., Abbey, S., Stewart, D. E., & Heathcote, E. J. (1998) · Gut · doi:10.1136/gut.43.5.705 · Cited by 237 · see citing works
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234 · see citing works
Self-citationThe Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 234 · see citing works
Recent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 223 · see citing works
Self-citationPoupon, R. E., Lindor, K. D., Parés, A. R., Chazouillères, O., Poupon, R. Y., & Heathcote, E. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00192-2 · Cited by 215 · see citing works
Self-citationAngulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00020.x · Cited by 203 · see citing works
Self-citationUrsodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation
Essell, J. H., Schroeder, M. T., Harman, G. S., Halvorson, R., Lew, V., Callander, N., Snyder, M., Lewis, S. K., Allerton, J. P., & Thompson, J. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_1-199806150-00002 · Cited by 189 · see citing works
Angulo, P., Jorgensen, R. A., Keach, J. C., Dickson, R. E., Smith, C., & Lindor, K. D. (2000) · Hepatology · doi:10.1002/hep.510310209 · Cited by 179 · see citing works
Self-citationUrsodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis
Lindor, K. D., Jorgensen, R. A., Therneau, T. M., Malinchoc, M., & Dickson, E. R. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.12.1137 · Cited by 166 · see citing works
Self-citationTrauner, M. A., & Graziadei (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00596.x · Cited by 149 · see citing works
Neuman, M. G., Angulo, P., Malkiewicz, I. M., Jorgensen, R. A., Shear, N. H., Dickson, E. R., Haber, J. A., Katz, G. G., & Lindor, K. D. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02672.x · Cited by 142 · see citing works
Self-citationIncreasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment
Lü, M., Zhou, Y., Haller, I. V., Romanelli, R. J., VanWormer, J. J., Rodriguez, C. V., Anderson, H., Boscarino, J. A., Schmidt, M. A., Daida, Y. G., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.033 · Cited by 137 · see citing works
Self-citationPrince, M. I., James, O., Holland, N. P., & Jones, D. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80385-2 · Cited by 136 · see citing works
Angulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80136-6 · Cited by 134 · see citing works
Self-citationEfficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis
Nakamura, K., Yoneda, M., Yokohama, S., Tamori, K., Sato, Y., Aso, K., Aoshima, M., Hasegawa, T., & MAKING, I. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1998.tb00674.x · Cited by 134 · see citing works
Biliary Atresia in The Netherlands: Outcome of Patients Diagnosed between 1987 and 2008
de Vries, W., de Langen, Z. J., Groen, H., Scheenstra, R., Peeters, P. M. J. G., Hulscher, J. B. F., & Verkade, H. J. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.09.061 · Cited by 127 · see citing works
Shi, J. Q., Wu, C., Lin, Y., Chen, Y.-X., Zhu, L., & Xie, W.-F. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00634.x · Cited by 123 · see citing works
Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis
Neuhauser, M., Bjornsson, E., Treeprasertsuk, S., Enders, F., Silveira, M., Talwalkar, J., & Lindor, K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.616 · Cited by 116 · see citing works
Self-citationVariant Forms of Cholestatic Diseases Involving Small Bile Ducts in Adults
Kim, W. R., Ludwig, J., & Lindor, K. D. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01999.x · Cited by 116 · see citing works
Self-citationUrsodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis
Lindor, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmct074694 · Cited by 115 · see citing works
Self-citationGuidelines for the management of primary biliary cirrhosis
Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 111 · see citing works
Functional and Structural Features of Cholangiocytes in Health and Disease
Maroni, L., Haibo, B., Ray, D., Zhou, T., Wan, Y., Meng, F., Marzioni, M., & Alpini, G. D. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.05.005 · Cited by 109 · see citing works
Bile Acid Therapy in Pediatric Hepatobiliary Disease: The Role of Ursodeoxycholic Acid
Balistreri, W. F. (1997) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-199705000-00016 · Cited by 106 · see citing works
Bowlus, C. L., Pockros, P. J., Kremer, A. E., Parés, A. R., Forman, L., Drenth, J. P. H., Ryder, S. D., Terracciano, L., Jin, Y., Liberman, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.09.050 · Cited by 105 · see citing works
Heubi, J. E., Wiechmann, D. A., Creutzinger, V., Setchell, K. D. R., Squires, R. H., Couser, R. J., & Rhodes, P. G. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.125802 · Cited by 98 · see citing works
MINIMAL CRITERIA FOR PLACEMENT OF ADULTS ON THE LIVER TRANSPLANT WAITING LIST
Lucey, M. R., Brown, K., Everson, G. T., Fung, J. J., Gish, R. G., Keefe, E. B., Kneteman, N. M., Lake, J. R., Martin, P. B., Rakela, J. L., et al. (1998) · Transplantation · doi:10.1097/00007890-199810150-00034 · Cited by 94 · see citing works
Park, S., Lee, M., Lee, H., Kim, H., Kım, K., Kim, W. S., Jung, C., Im, Y., Yoon, S., Wk, K., et al. (2002) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703342 · Cited by 93 · see citing works
Angulo, P., Patel, T. C., Jorgensen, R. A., Therneau, T. M., & Lindor, K. D. (2000) · Hepatology · doi:10.1053/jhep.2000.18663 · Cited by 88 · see citing works
Self-citationKaplan, M. M., Cheng, S., Price, L. L., & Bonis, P. A. L. (2004) · Hepatology · doi:10.1002/hep.20103 · Cited by 87 · see citing works
Use of ursodeoxycholic acid in liver diseases
Kumar, D., & Tandon, R. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02376.x · Cited by 87 · see citing works
Karlsen, T. H., Vesterhus, M. N., & Boberg, K. M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12581 · Cited by 86 · see citing works
Ursodeoxycholic acid for primary biliary cirrhosis
Gluud, C. N., & Christensen, E. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551 · Cited by 84 · see citing works
Wolfhagen, F. H. J., van Hoogstraten, H. J. F., van Buuren, H. R., Henegouwen, G. P. V. B., ten Kate, F. J. W., Hop, W. C. J., van der Hoek, E. W., Kerbert-Dreteler, M. J., van Lijf, H. H., den Ouden, J. W., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80254-7 · Cited by 83 · see citing works
Ursodeoxycholic acid for primary biliary cirrhosis
Gong, Y., Huang, Z. B., Christensen, E., & Gluud, C. N. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub2 · Cited by 80 · see citing works
Willot, S., Uhlen, S., Michaud, L., Briand, G., Bonnevalle, M., Sfeir, R., & Gottrand, F. (2008) · PEDIATRICS · doi:10.1542/peds.2008-0986 · Cited by 77 · see citing works
Ursodeoxycholic acid treatment of vanishing bile duct syndromes
Pusl, T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i22.3487 · Cited by 76 · see citing works
Population‐based epidemiology of primary biliary cirrhosis in South Korea
Kim, K., Ki, M., Choi, H. Y., Kim, B. H., Jang, E. S., & Jeong, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13448 · Cited by 75 · see citing works
Cirrhosis and autoimmune liver disease: Current understanding
Liberal, R., & Grant, C. R. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i28.1157 · Cited by 72 · see citing works
Silveira, M. G., Gossard, A. A., Stahler, A. C., Jorgensen, R. A., Petz, J. L., Ali, A. H., & Lindor, K. D. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000387 · Cited by 64 · see citing works
Self-citationOmata, M., Yoshida, H., Toyota, J., Tomita, E., Nishiguchi, S., Hayashi, N., Iino, S., Makino, I., Okita, K., Toda, G., et al. (2007) · Gut · doi:10.1136/gut.2007.120956 · Cited by 64 · see citing works
Mason, A. L., Farr, G. H., Xu, L., Hübscher, S. G., & Neuberger, J. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40741.x · Cited by 59 · see citing works
Mason, A. L., Lindor, K., Bacon, B. R., Vincent, C., Neuberger, J., & Wasilenko, S. T. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03799.x · Cited by 56 · see citing works
Self-citationPapatheodoridis, G., Hadziyannis, E. S., Deutsch, M. J., & Hadziyannis, S. J. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05923.x · Cited by 55 · see citing works
Methotrexate for primary biliary cirrhosis
Giljača, V., Poropat, G., Štimac, D., & Gluud, C. N. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004385.pub3 · Cited by 53 · see citing works
Pharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 54 · see citing works
Cost–Effectiveness of Ursodeoxycholic Acid Therapy in Primary Biliary Cirrhosis
Pasha, T. M., Heathcote, J., Gabriel, S. E., Cauch‐Dudek, K., Jorgensen, R. A., Therneau, T. M., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290116 · Cited by 53 · see citing works
Self-citationAlmasio, P. L., Floreani, A., Chiaramonte, M., Provenzano, G., Battezzati, P. M., Crosignani, A., Podda, M., Todros, L., Rosina, F., Saccoccio, G., et al. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00869.x · Cited by 53 · see citing works
Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the pastissues for the future
Poupon, R. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80232-9 · Cited by 54 · see citing works
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders
Trauner, M. A., Halilbasic, E., Claudel, T., Steinacher, D., Fuchs, C. D., Moustafa, T., Pollheimer, M. J., Krones, E., Kienbacher, C., Traussnigg, S., et al. (2015) · Digestive Diseases · doi:10.1159/000371904 · Cited by 49 · see citing works
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 50 · see citing works
Self-citationTreatment of autoimmune liver disease: current and future therapeutic options
Trivedi, P. J., & Hirschfield, G. M. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313478646 · Cited by 49 · see citing works
Combes, B., Luketic, V. A., Peters, M. G., Zetterman, R. K., García–Tsao, G., Muñoz, S. J., Lin, D.-Y., Flye, N. L., & Carithers, R. L. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04047.x · Cited by 47 · see citing works
Bonis, P. A., & Kaplan, M. M. (1999) · Gastroenterology · doi:10.1053/gast.1999.0029900395 · Cited by 49 · see citing works
Lammert, C. S., Juran, B. D., Schlicht, E. M., Chan, L. L., Atkinson, E. J., de Andrade, M., & Lazaridis, K. N. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0903-1 · Cited by 46 · see citing works
Clinical features and management of primary biliary cirrhosis
Crosignani, A., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 46 · see citing works
PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS
Angulo, P., & Lindor, K. D. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70084-2 · Cited by 46 · see citing works
Self-citationNatural History of Primary Biliary Cirrhosis
Mayo, M. J. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.012 · Cited by 45 · see citing works
Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era
Goel, A., & Kim, W. R. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.007 · Cited by 45 · see citing works
van Hoogstraten, H. J. F., Hansen, B. E., van Buuren, H. R., ten Kate, F. J. W., Henegouwen, G. P. V. B., & Schalm, S. W. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80222-0 · Cited by 43 · see citing works
Prognostic models in chronic liver disease: validity, usefulness and future role.
Christensen, E. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80481-3 · Cited by 43 · see citing works
Treatment of primary sclerosing cholangitis in children
Laborda, T. J., Jensen, M. K., Kavan, M., & Deneau, M. R. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i1.19 · Cited by 42 · see citing works
Methotrexate therapy for primary biliary cirrhosis
Bach, N., Bodian, C., Bodenheimer, H. C., Croen, E. C., Berk, P. D., Thung, S. N., Lindor, K. D., Therneau, T., & Schaffner, F. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07173.x · Cited by 41 · see citing works
Self-citationMedical and Nutritional Management of Cholestasis in Infants and Children
Feranchak, A. P., & Sokol, R. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.012 · Cited by 40 · see citing works
Christensen, E., Gunson, B., & Neuberger, J. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80075-0 · Cited by 40 · see citing works
HGV: hepatitis G virus or harmless G virus?
Kew, M. C., & Kassianides, C. (1996) · The Lancet · doi:10.1016/s0140-6736(96)98020-4 · Cited by 39 · see citing works
Treatment of primary biliary cholangitis ursodeoxycholic acid non‐responders: A systematic review
Suraweera, D., Rahal, H., Jimenez, M., Viramontes, M., Choi, G., & Saab, S. (2017) · Liver International · doi:10.1111/liv.13477 · Cited by 38 · see citing works
Primary biliary cirrhosis: new perspectives in diagnosis and treatment
Prince, M. I., & Jones, D. E. J. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.894.199 · Cited by 36 · see citing works
Goh, S., Gull, S. E., & Alexander, G. (2001) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1016/s0306-5456(00)00189-3 · Cited by 36 · see citing works
van Hoogstraten, H. J. F., de Smet, M. B. M., Renooij, Breed, Engels, den Ouden-Muller, J. W., Rijk, Smit, Zwertbroek, Hop, et al. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00395.x · Cited by 35 · see citing works
Boonstra, K., Bokelaar, R., Stadhouders, P., Tuynman, H., Poen, A., van Nieuwkerk, K., Witteman, E., Hamann, D., Witteman, B., Beuers, U., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9530-z · Cited by 34 · see citing works
The Role of Lipophilic Bile Acids in the Development of Cirrhotic Cardiomyopathy
Zavecz, J. H., & Battarbee, H. D. (2010) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9069-8 · Cited by 28 · see citing works
Current pharmacotherapy for cholestatic liver disease
Carey, E. J., & Lindor, K. D. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.736491 · Cited by 29 · see citing works
Self-citationA phenomenological study of fatigue in patients with primary biliary cirrhosis
Jorgensen, R. A. (2006) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2006.03958.x · Cited by 29 · see citing works
Self-citationOptions for Treatment of Primary Biliary Cirrhosis
Oo, Y. H., & Neuberger, J. (2004) · Drugs · doi:10.2165/00003495-200464200-00001 · Cited by 28 · see citing works
Babatin, M. A., Sanai, F. M., & Swain, M. G. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03048.x · Cited by 29 · see citing works
Lirussi, F., Beccarello, A., Bortolato, L., Morselli‐Labate, A. M., Crovatto, M., Ceselli, S., Santini, G., & Crepaldi, G. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00066.x · Cited by 29 · see citing works
GUDC Inhibits CytochromecRelease from Human Cholangiocyte Mitochondria
Que, F. G., Phan, V., Phan, V. H., LaRusso, N. F., & Gores, G. J. (1999) · Journal of Surgical Research · doi:10.1006/jsre.1999.5574 · Cited by 29 · see citing works
Network Meta-Analysis of Randomized Controlled Trials
Zhu, G., Shi, K., Huang, S., Huang, G., Lin, Y.-Q., Zhou, Z., Braddock, M., Chen, Y., & Zheng, M. (2015) · Medicine · doi:10.1097/md.0000000000000609 · Cited by 27 · see citing works
Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27 · see citing works
Self-citationFatigue in cholestatic liver disease—a perplexing symptom
Kumar, D., & Tandon, R. K. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.921.404 · Cited by 26 · see citing works
Botero, R. C., & Lucey, M. R. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00052-7 · Cited by 26 · see citing works
The diagnosis and treatment of primary biliary cirrhosis
Kim, K., & Jeong, S. (2011) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2011.17.3.173 · Cited by 25 · see citing works
- Authors
- Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E.
- Affiliations
- Mayo Clinic (US)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1996-05
- Volume
- 110
- Issue
- 5
- Pages
- 1515-1518
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2075432722
- Cited by
- 228
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 7 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 8 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 11 · 2014: 10 · 2013: 9 · 2012: 5
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, survival, mortality, liver transplantation, Mayo risk score, long-term treatment, intention-to-treat analysis
- MeSH terms
- Adult, Double-Blind Method, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Prospective Studies, Ursodeoxycholic Acid, Survival Rate, Proportional Hazards Models, Liver Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
